ARCHIVES

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

DCT Board Approves Recompetition Of Clinical Trials, Other Contracts, New BNCT Grants

October 28, 1988

Behavior Scientists To Discuss Cancer Patient Rehabilitation

January 17, 1975

NIH To Sponsor Animal Care, Human Protection Workshop

February 21, 1986

DCT Board Approves Contract Recompetitions Worth 44.8 Million In First Year Awards

November 5, 1982

HHS Forms Patient Safety Task Force; Henry Ford Health System Receives $40M.

April 27, 2001

NCI advisors approve recompetition of $62 million phase II contracts program.

November 19, 2004